{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:30:20Z","timestamp":1791217820049,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA021765"],"award-info":[{"award-number":["P30 CA021765"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R25 CA23944"],"award-info":[{"award-number":["R25 CA23944"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.bbmt.2015.08.013","type":"journal-article","created":{"date-parts":[[2015,8,14]],"date-time":"2015-08-14T02:17:39Z","timestamp":1439518659000},"page":"2148-2153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Escalation to High-Dose Defibrotide in Patients with Hepatic Veno-Occlusive Disease"],"prefix":"10.1016","volume":"21","author":[{"given":"Brandon M.","family":"Triplett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani I.","family":"Kuttab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guolian","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2015.08.013_bib1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.bmt.1704069","article-title":"Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients","volume":"32","author":"Barker","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.08.013_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","article-title":"Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome","volume":"16","author":"Coppell","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.08.013_bib3","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1055\/s-2007-976173","article-title":"Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide","volume":"33","author":"Ho","year":"2007","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.bbmt.2015.08.013_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s002770050364","article-title":"Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications","volume":"76","author":"Nurnberger","year":"1998","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2015.08.013_bib5","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00062752-200311000-00010","article-title":"Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment","volume":"10","author":"Wadleigh","year":"2003","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.bbmt.2015.08.013_bib6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep.1840040121","article-title":"Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors","volume":"4","author":"McDonald","year":"1984","journal-title":"Hepatology"},{"key":"10.1016\/j.bbmt.2015.08.013_bib7","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Venoocclusive disease of the liver following bone marrow transplantation","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2015.08.013_bib8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","article-title":"Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients","volume":"118","author":"McDonald","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2015.08.013_bib9","first-page":"3599","volume":"92","author":"Carreras","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.08.013_bib10","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1200\/JCO.1993.11.9.1729","article-title":"Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation","volume":"11","author":"Bearman","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.08.013_bib11","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood.V89.5.1501","article-title":"Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients","volume":"89","author":"Bearman","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.08.013_bib12","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.bbmt.2010.02.009","article-title":"Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial","volume":"16","author":"Richardson","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.08.013_bib13","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood-2002-04-1216","article-title":"Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.08.013_bib14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/1024533031000084231","article-title":"Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF)","volume":"8","author":"Kaleelrahman","year":"2003","journal-title":"Hematology"},{"key":"10.1016\/j.bbmt.2015.08.013_bib15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1517\/14740338.2012.749855","article-title":"Drug safety evaluation of defibrotide","volume":"12","author":"Richardson","year":"2013","journal-title":"Exp Opin Drug Saf"},{"key":"10.1016\/j.bbmt.2015.08.013_bib16","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.bbmt.2011.06.006","article-title":"The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade","volume":"17","author":"Carreras","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.08.013_bib17","first-page":"737","article-title":"Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population","volume":"92","author":"Richardson","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.08.013_bib18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1586\/ehm.12.18","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation","volume":"5","author":"Corbacioglu","year":"2012","journal-title":"Exp Rev Hematol"},{"key":"10.1016\/j.bbmt.2015.08.013_bib19","first-page":"1122","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study","volume":"111","author":"Chopra","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2015.08.013_bib20","first-page":"1396","article-title":"A\u00a0prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation","volume":"90","author":"Cesaro","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2015.08.013_bib21","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/pbc.20934","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease in children","volume":"48","author":"Bulley","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2015.08.013_bib22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.bmt.1704329","article-title":"Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention","volume":"33","author":"Corbacioglu","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.08.013_bib23","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A\u00a0class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"10.1016\/j.bbmt.2015.08.013_bib24","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2307\/2530374","article-title":"The analysis of failure times in the presence of competing risks","volume":"34","author":"Prentice","year":"1978","journal-title":"Biometrics"},{"key":"10.1016\/j.bbmt.2015.08.013_bib25","unstructured":"R: A language and environment for statistical computing. R Foundation for Statistical Computing; Vienna, Austria, 2012."},{"key":"10.1016\/j.bbmt.2015.08.013_bib26","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1182\/blood.V122.21.700.700","article-title":"Results of the large prospective study on the use of defibrotide in the treatment of hepatic veno-occlusive disease in hematopoietic stem cell transplant. early intervention improves outcome\u2014updated results of a treatment IND expanded access protocol","volume":"122","author":"Richardson","year":"2013","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387911500542X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387911500542X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:52:35Z","timestamp":1761058355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108387911500542X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S108387911500542X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.08.013","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Escalation to High-Dose Defibrotide in Patients with Hepatic Veno-Occlusive Disease","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}